Avience Biomedicals IPO Financials
The Avience Biomedicals IPO provide an overview of the company's performance over the previous financial periods. Investors can evaluate key financial metrics such as assets, revenue, profit after tax (PAT), net worth, reserves & surplus, and total borrowings to assess the company's financial strength, profitability, and long-term growth potential before investing in the IPO.
As of 31 Jan 2026, Avience Biomedicals Limited reported assets of ₹51.96 crore, revenue of ₹28.85 crore, and a profit after tax (PAT) of ₹4.18 crore. The company had a net worth of ₹24.7 crore and reserves & surplus of ₹20.67 crore, and total borrowings are 17.17 crore.
Revenue increased by 2.39% in 31 Mar 2025 and decreased by 43.67% in 31 Mar 2024, while Profit After Tax (PAT) grew by 22.97% in 31 Mar 2025 and declined by 61.48% in 31 Mar 2024, respectively.
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
Avience Biomedicals Limited Financials (₹ in Crores)
| Particular | 31 Jan 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 51.96 | 43.6 | 25.63 |
| Revenue | 28.85 | 29.54 | 16.64 |
| Profit After Tax | 4.18 | 5.14 | 1.98 |
| Net Worth | 24.7 | 20.52 | 6.05 |
| Reserve & Surplus | 20.67 | 16.49 | 2.77 |
| Total Borrowings | 17.17 | 13.75 | 7.73 |
EPS Pre
12.74%
EPS Post
9.15%
P/E Pre
16.33
P/E (Post Issue)
22.74x
Company Financial Information
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Revenue of Avience Biomedicals Limited ?
Avience Biomedicals Limited reported revenue of ₹28.85 crore as of 31 Jan 2026 . Revenue figures from the Avience Biomedicals IPO provide insights into sales growth, market demand, and business scalability.
What is the Profit After Tax (PAT) of Avience Biomedicals Limited ?
Avience Biomedicals Limited reported a Profit After Tax (PAT) of ₹4.18 crore as of 31 Jan 2026 . PAT represents the company's net profit after deducting all operating expenses, interest, taxes, and other applicable charges, making it a key indicator of overall profitability.
What is the PE Ratio of Avience Biomedicals Limited ?
Avience Biomedicals Limited has a Price-to-Earnings (P/E) ratio of 16.33x based on the IPO issue price. The P/E ratio compares the company's share price with its earnings per share (EPS) and is a commonly used valuation metric to assess whether a stock is fairly valued relative to its earnings and industry peers.